Isep charity care action started, benefiting poor rheumatism patients.
In 2009, Yisaipu &; Reg won the 11th China Patent Gold Award.
Approved by the Ministry of Science and Technology, the State Key Laboratory of Antibody Drugs was approved for construction.
The company and its partners signed cooperation agreements and letters of intent with Brazilian pharmaceutical manufacturers.
In 2008, the National Development and Reform Commission approved the construction of a national engineering research center for antibody drugs. This center is the first national antibody drug research and development and industrialization institution in China.
In 2007, Yisaipu &; Reg won "National Technological Invention Award" and "National Natural Science Award".
In 2006, the first biological preparation in the field of rheumatism was listed in China.
In 2005, the company moved to No.399, Libing Road, Zhangjiang Hi-tech Park.
Shanghai Antibody Engineering Technology Research Center was established.
14 projects obtained invention patent certificates, including 3 international patents.
In 2004, new drugs for non-Hodgkin's lymphoma, breast cancer and liver cancer were approved for clinical research.
One tumor vaccine project has obtained the US patent certificate, and the other five projects have obtained the invention patent certificate.
In 2003, new drugs for moderate and severe rheumatoid arthritis, hemorrhagic diseases and rheumatoid arthritis were approved by clinical research respectively.
In 2002, Shanghai CITIC Guo Jian Pharmaceutical Co., Ltd. was established.
The company established the enterprise postdoctoral research center.
The company established Shanghai Key Laboratory of Cell Engineering.
1998 Shanghai Zhangjiang biotechnology research center was established.